 |
| 10.06.08 |
|
Celecure received excellent ranking under Europe's funding program for the SME's the EUREKA's Eurostars Programme. With the new funding available Celecure plans to fasten the development of SB101.
SB101 is a novel angiogenesis inhibitor, based on parts of the endogenous protein CD44 working via a novel mechanism not previously ascribed to CD44. SB101 binds to endothelial cells and specifically blocks their proliferation. SB101 works efficiently and at very low doses in different experimental animal models to block angiogenesis and tumour growth. SB101 has the potential to be a significant breakthrough in cancer therapy by its novel mechanism of action. |
|
|
Akadeemia 15, 12618 Tallinn, Estonia